Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk UTUC (DISTINCT-II)
NCT07584733Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, tislelizumab in upper tract urothelial carcinoma (UTUC), sponsored by Renji Hospital. Planned start May 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintislelizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT07584733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584733.